Int.J.Curr.Microbiol.App.Sci (2026) *15*(9): 1-8

International Journal of Current Microbiology and Applied Sciences
ISSN: 2319-7706 **Volume 15 Number 9 (2026)**
Journal homepage: http://www.ijcmas.com

Review Article https://doi.org/10.20546/ijcmas.2026.1509.001

Lobar Pneumonia: Clinical Update, Advanced Management, and Emerging Science

Sadiq M. A. AL-Hiti[1*], Ajwad Awad Assumaidaee[2] and Maryam Maadh Badr[2]

[1]Al-Yarmouk University College, Iraq - Diyala – Baqubah, Iraq
[2]Department of Clinical Laboratory Sciences, College of Pharmacy, University of Baghdad, Baghdad, Iraq

**Corresponding author*

Keywords
Lobar Pneumonia
Streptococcus pneumoniae
Antimicrobial Resistance
Hepatization

Article Info

Received:
05 July 2026
Accepted:
22 August 2026
Available Online:
10 September 2026

A B S T R A C T

Lobar pneumonia is a distinct anatomical pattern of acute pneumonia characterized by relatively homogeneous consolidation involving a substantial portion of a pulmonary lobe. Unlike bronchopneumonia, which typically produces patchy involvement of individual lobules, lobar pneumonia is associated with contiguous inflammatory spread and has historically been described through four pathological stages: congestion, red hepatization, gray hepatization, and resolution. Although the classical presentation has become less frequent with early antimicrobial intervention and improved diagnostic practices, lobar consolidation remains an important clinical manifestation of severe bacterial respiratory infection. Streptococcus pneumoniae remains a prominent etiological agent, while other bacterial, viral, and fungal pathogens may contribute depending on the clinical setting and host characteristics. Community-acquired, hospital-acquired, and ventilator-associated pneumonia differ in their epidemiological characteristics and predominant pathogens, including antimicrobial-resistant organisms such as methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative bacilli. Emerging pathogens and hypervirulent strains further complicate diagnosis and management. This review provides an updated overview of lobar pneumonia, encompassing its classification, etiological spectrum, pathophysiology, clinical relevance, histopathological characteristics, and emerging resistant pathogens. Particular emphasis is placed on contemporary changes in disease presentation, pathogen distribution, and management considerations, highlighting the continuing importance of accurate diagnosis, appropriate antimicrobial therapy, and recognition of evolving patterns of pneumonia.

Introduction

Lobar pneumonia is a distinct anatomical manifestation of acute bacterial pneumonia characterized by the homogeneous consolidation of a large, continuous piece of the lung parenchyma, typically affecting an entire lobe.

Unlike bronchopneumonia, which affects lobules in a patchy distribution, lobar pneumonia is characterized by the continuous spread of inflammation through the pores of Kohn and canals of Lambert. (1) Recent studies show that "pure" lobar pneumonia is becoming less common due to early antibiotic intervention, although it is still a significant phenotype associated with high- inflammatory states and particular bacteria like Streptococcus pneumoniae. (2)

Many attempts have been made to classify pneumonia based on a number of variables, such as the origin, the clinical setting in which the infection was acquired, and the pattern of lung parenchyma involvement. This article uses the classification system of the American Thoracic Society to analyze pneumonia.

Community-Acquired Pneumonia (CAP)

Any pneumonia acquired outside of a hospital in a community setting.*3+

Hospital-Acquired Pneumonia (HAP)

HAP refers to any pneumonia that develops 48 hours after being admitted to an inpatient facility, such as a hospital, and is not incubating at the time of admission. The distinction between hospital-acquired and healthcare-associated pneumonia is made clearer by this classification.

Community-acquired pneumonia (HAP) is currently defined as any pneumonia acquired in assisted living facilities, rehabilitation centers, or other healthcare institutions; a hospital setting is required to designate pneumonia as HAP.*4+

Ventilator Associated Pneumonia (VAP)

VAP refers to any pneumonia that appears 48 hours following endotracheal intubation.*5+

These classifications have helped identify the common pathogens that cause each form of pneumonia and have also contributed to the development of therapeutic guidelines for effective treatment in both inpatient and outpatient settings.

Pneumonia has also been researched historically in the following methods, depending on involvement patterns:

- Only one lung lobe is affected by lobar pneumonia, sometimes referred to as localized non-segmental pneumonia *6+.

Etiology

Even though determining the etiologic agent of pneumonia is crucial for both effective treatment and maintaining epidemiological data, this is rarely observed in clinical practice.

Less than 10% of patients who visit the emergency room have a single cause of pneumonia, according to extensive evaluations.*7+ However, the previously mentioned topics can be used to study the most prevalent species that cause pneumonia.

Community-Acquired Pneumonia

Bacterial causes

In the past, their ease of cultural positively has led to their classification as "typical" and "atypical" species. Moraxella catarrhalis, Group A Streptococcus, Haemophilus influenzae, Pneumococcus, and a variety of aerobic and anaerobic gram-negative bacteria are common characteristic organisms. Among the atypical organisms frequently encountered in clinical practice are Legionella, Mycoplasma, and Chlamydia.*8+ Mycoplasma pneumoniae, Staphylococcus aureus, Streptococcus pneumoniae, and gram-negative enteric bacteria are the most frequent bacterial causes of CAP in the United States.*9+

Viral causes

Patients with CAP frequently have viral infections in their nasopharynx. It is still unclear if secondary bacterial agents have a part in the pathogenesis or if they are the main cause. However, influenza virus, respiratory syncytial virus, parainfluenza virus, and adenoviruses are among the most common viral agents linked to CAP in the United States. *9+

Fungal causes

HIV and organ transplant recipients are two predisposing immunocompromised conditions that are typically linked to fungal infections. The fact that some fungal species can cause pneumonia in immunocompetent people is commonly disregarded, though. This could delay diagnosis and have negative consequences. The three most prevalent ones in North America are Coccidioides, Blastomyces, and Histoplasma. *10+

Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia

- Due to the substantial overlap in the etiologic agents, it is appropriate to assess hospitalized patients with pneumonia who are ventilated and those who are not. Acinetobacter, Enterobacter, Pseudomonas aerugenosa, and Escherichia coli are examples of gram-negative bacteria.
- Gram-positive cocci that are resistant to and sensitive to methicillin, like Staphylococcus aureus, however the latter is more prevalent *11+.*12+

- Other viruses and fungi that are more prevalent in people with severe diseases and compromised immune systems

The Dominance of Streptococcus pneumoniae

30–50% of community-acquired pneumonia (CAP) cases worldwide are caused by Streptococcus pneumoniae, also known as Pneumococcus, despite widespread immunization.

Mechanisms of Virulence: The toxin pneumolysin causes direct cytotoxic damage to the alveolar-capillary membrane, permitting the enormous fluid exudation typical of lobar consolidation, while the pneumococcal capsule prevents phagocytosis.*13+

The "Post-Viral" Bacterial Pneumonia Surge

The mechanism of secondary bacterial lobar pneumonia after viral infections (influenza, SARS-CoV-2, RSV) is one of the main topics in 2024–2025 literature.*14+

Mechanism of Superinfection: According to recent reviews (such as Frontiers in Microbiology, 2025), viral infections cause lung microbiome disruption and alveolar macrophage depletion. As a result, the lower respiratory tract becomes a "permitted window" for commensal bacteria like S. pneumoniae or S. aureus.*15+
Clinical Impact: Necrotizing pneumonia and empyema are more common in patients with post-viral lobar pneumonia.

Emerging and Resistant Pathogens

In individuals with diabetes and alcohol use disorders, Klebsiella pneumoniae is still a major cause of severe lobar pneumonia, often known as Friedl ("'s pneumonia"). The data from 2024 shows an increase in hypervirulent strains that produce imaging "bulging fissure" signals.

Staphylococcus aureus (MRSA): More frequently found in younger individuals who have lobar consolidation after influenza.

Legionella pneumophila: Continues to be a major contributor to lobar pathology during outbreaks, frequently manifesting as gastrointestinal symptoms and hyponatremia.

Pathophysiology: The Four Stages Revisited

Four phases are described by classic pathology. These phases frequently overlap locally, according to recent autopsy and imaging investigations (2024).

Traffic (First 24 Hours)

Pathology: Intra-alveolar edema and vascular enlargement.

Clinical: The lung feels swampy and heavy. In the serous fluid, bacteria multiply quickly.

Red Hepatization (Days 2-4)

Pathology: Extensive fibrin, neutrophil, and erythrocyte exudation. The lobe has a solid, crimson appearance that resembles the liver (hepatization). Significant V/Q mismatch and hypoxemia result from the afflicted lobe's lack of gas exchange.

Gray Hepatization (Days 4–8)

Pathology: Neutrophils and fibrin are still present, but erythrocytes break down. The lobe turns dry and gray.

Significance: The possibility of septic shock and the peak of the systemic inflammatory response (SIRS) are frequently associated with this stage.

Resolution (Day 8+)

Pathology: The enzymatic waste is broken down by macrophages.

Result: Unlike interstitial pneumonias, architecture is usually recovered without irreversible fibrosis.

Histopathology

The two primary categories of pneumonia histology are lobar pneumonia and bronchopneumonia/lobularpneumonia.

Lobar Pneumonia

Diffuse consolidation throughout the whole lung lobe is known as lobar pneumonia. The four stages of its evolution are as follows:

- Congestion: This stage is characterized by an accumulation of infectious organism-rich alveolar fluid, extensive congestion, vascular engorgement, and lung tissue that looks abnormally heavy and swampy. Red blood cells (RBC) and neutrophils are currently scarce.
- • Red hepatization: The alveolar fluid has a discernible infiltration of red blood cells, neutrophils, and fibrin. The term "hepatization" describes the lungs' unattractive appearance, which is red and hard like a liver.
- Gray hepatization: The disintegration of red blood cells and fibrinopurulent exudates results in a shift in color from red to gray.
- Resolution: Exudates are eliminated by resident macrophages, either with or without the formation of long-lasting scar tissue.

Advanced Diagnostics

Rapid molecular techniques have caused the diagnostic paradigm to change from "treat then test" to "test fast, treat narrow".

Rapid Syndromic Molecular Testing

The use of multiplex PCR panels (such as the BioFire FilmArray Pneumonia Panel) for patients hospitalized with severe lobar pneumonia is becoming more and more supported by the 2025 IDSA/ATS revisions.

Capabilities: In less than two hours, it can identify the genetic material of around eighteen bacteria, nine viruses, and antibiotic resistance genes (such as blaKPC for carbapenemase and mecA for MRSA).

Impact: When compared to standard cultures, a 2025 study showed that employing these panels shortened the time to appropriate antibiotic treatment by more than 40 hours.

Lung Ultrasound (LUS): The New Standard

Guidelines for 2025 Note: For identifying consolidation in emergency situations, the American Thoracic Society (ATS) 2025 update highlights lung ultrasound as a better option than bedside chest X-rays (CXR).

Lobar Pneumonia Diagnostic Standards on LUS:

Tissue-like Sign Hepatization, where the lung resembles the liver.

Shred Sign: An uneven line between the consolidated and aerated lungs.

Dynamic Air Bronchograms: Atelectasis is ruled out and pneumonia is confirmed by white, moving flecks inside the consolidation, which indicate air in the bronchi.

Biomarkers

The gold standard for differentiating bacterial lobar pneumonia from viral causes is still procalcitonin (PCT). Bacterial aetiology is highly supported by a PCT > 0.25 µg/L. MR-proADM:

Compared to lactate or CRP alone, a more recent biomarker called mid- regional pro-adrenomedullin is becoming more popular in 2024 as a better predictor of death and organ failure.

Treatment and Management Protocols

The shift to shorter, higher-dose antibiotic courses is the biggest change in 2024–2025 ("Short is Safe").

Pharmacological Management (Adults)

Outpatient (no comorbidities, healthy)

First Line: Doxycycline (100 mg BID) OR Amoxicillin (1 g TID).

Note: In areas where pneumococcal resistance is greater than 25%, which is now the majority of the US and Europe, macrolides (azithromycin) are no longer advised as monotherapy.

Outpatient (diabetes, heart disease, and COPD comorbidities)

Combination Therapy: Amoxicillin/Clavulanate (Augmentin) or Cephalosporin (Cefpodoxime) with a macrolide (Azithromycin) or Doxycycline.

As a monotherapy, respiratory fluoroquinolones (Levofloxacin 750 mg or Moxifloxacin 400 mg) are utilized.





Non-Severe Inpatient

Standard: 500 mg IV/PO of azithromycin with 1-2 g IV of ceftriaxone.

Azithromycin: Why? Its immunomodulatory advantages in pneumococcal pneumonia, which lower mortality even beyond its bactericidal activity, have been confirmed by recent studies.

Inpatient (ICU/severe)

Ceftriaxone + Levofloxacin OR Ceftriaxone + Azithromycin is the recommended regimen. MRSA

Coverage: If there are risk indicators (past isolation, recent hospitalization), add Vancomycin or Linezolid.
Coverage of Pseudomonas: Replace Ceftriaxone with Cefepime or Piperacillin- Tazobactam (Zosyn).

New Antibiotics (2024–2025 Approvals & Data)

Omadacycline (Nuzyra): A modern tetracycline effective against resistant S. pneumoniae and MRSA. A 2025 cost-effectiveness study highlighted its utility as an oral step-down option to facilitate early discharge.

Lefamulin (Xenleta): A pleuromutilin antibiotic. A 2025 pooled analysis confirmed it is non-inferior to moxifloxacin, with a safety profile specifically beneficial for elderly patients with cardiac comorbidities (no QT prolongation risk).

Aztreonam-Avibactam (Emblaveo): Approved in 2024, this is reserved for gram- negative lobar pneumonia caused by metallo-beta-lactamase (MBL) producing organisms.

Duration of Therapy: The "3-Day" Shift

New Evidence: According to the 2025 ATS Guideline Update and recent pediatric revisions (NICE 2025), a course of antibiotics lasting three to five days is just as effective as the conventional seven to ten days for kids who stabilize (afebrile for 48 hours). This is essential for lowering resistance and harm to the microbiota.

Adjunctive Corticosteroids

Recommendation: The 2024 recommendations suggest either methylprednisolone or hydrocortisone (200 mg/day continuous infusion) for severe CAP (admitted to the intensive care unit or requiring high-flow oxygen) in order to lower mortality and ventilation requirements. For less severe situations, it is not advised.

Complications and Long-Term Prognosis

Thoracic Complications

In 40–50% of lobar pneumonias, parapneumonic effusion and empyema are present. Early sampling (thoracentesis) is recommended by 2024 standards. Chest tube drainage is required if the pH is less than 7.20 or the glucose level is less than 60 mg/dL.

Necrotizing pneumonia is an uncommon but increasingly common complication that causes cavitation inside the consolidation and is associated with PVL-positive S. aureus.

Systemic Sequelae: The "Cardiac-Pneumonia" Connection

Lobar pneumonia is an independent risk factor for acute myocardial infarction (heart attack) and new-onset atrial fibrillation, according to a seminal 2025 Systematic Review (European Respiratory Review).

Mechanism: Atherosclerotic plaques become unstable due to systemic inflammation.

Management: It is now recommended that clinicians keep an eye on cardiac biomarkers (Troponin) in older patients with pneumonia and make sure statin medication is optimized after discharge.

Prognosis

Mortality: Stays between 5 and 10% for hospitalized patients, but rises to above 30% for those who need to be admitted to the intensive care unit.

Recovery: Clinical recovery is faster than radiological resolution.

It might take six to eight weeks for the X-ray to show the consolidation. For smokers over 50, a follow-up X-ray at six weeks is advised to rule out underlying lung cancer ("post-obstructive pneumonia").

Prevention: The New Vaccine Era (2024–2025)

The approval of higher-valency conjugate vaccinations has transformed prevention tactics.

Pneumococcal Vaccines (Adults)

As of October 2024, PCV20 (Prevnar 20) or PCV21 (Capvaxive) are recommended by the ACIP (Advisory Committee on Immunization Practices):

Suggested for all persons over 50 (reduced from 65).

Additionally, for people aged 19 to 49 who have risk factors (diabetes, asthma, smoking).

Benefit: Compliance is made easier by the fact that these "one-and-done" vaccinations don't call for a second dose of PPSV23.

Details of PCV21: Approved in the middle of 2024, it offers more coverage than earlier versions and especially targets serotypes that cause adult invasive illness.

Viral Vaccines

Adults over 60 (or 50–59 with risk factors) are now advised to have the RSV vaccine (Arexvy/Abrysvo). The risk of subsequent bacterial lobar pneumonia is greatly reduced by preventing RSV.

Author Contributions

Sadiq M. A. AL-Hiti: Investigation, formal analysis, writing—original draft. Ajwad Awad Assumaidaee: Validation, methodology, writing—reviewing. Maryam Maadh Badr:—Formal analysis, writing—review and editing.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethical Approval Not applicable.

Consent to Participate Not applicable.

Consent to Publish Not applicable.

Conflict of Interest The authors declare no competing interests.

References

1. Jain, V., Vashisht, R., Yilmaz, G. and Bhardwaj, A., 2018. Pneumonia pathology.
2. Antonitsch, L., Gallob, R., Weidinger, G. and Kettenbach, J., 2021. New insights and antimicrobial stewardship opportunities in viral pneumonia: five lung ultrasound cases. Wiener klinische Wochenschrift, 133(21), pp.1208-1214.
3. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG., Infectious Diseases Society of America. American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007 Mar 01; 44 Suppl 2(Suppl 2): S27-72.
4. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratalà J, El Solh AA, Ewig S, Fey PD, File TM, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL. Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016 Sep 01; 63(5): 575-82.
5. Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med. 2006 Dec 21; 355(25): 2619-30.
6. Gharib AM, Stern EJ. Radiology of pneumonia. Med Clin North Am. 2001 Nov; 85(6): 1461-91, x.
7. Bartlett JG. Diagnostic tests for agents of community-acquired pneumonia. Clin Infect Dis. 2011 May; 52 Suppl 4: S296-304. *PubMed+
8. Sattar SBA, Nguyen AD, Sharma S. StatPearls *Internet+. StatPearls Publishing; Treasure Island (FL): Feb 26, 2024. Bacterial Pneumonia.
9. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, Reed C, Grijalva CG, Anderson EJ, Courtney DM, Chappell JD, Qi C, Hart EM, Carroll F, Trabue C, Donnelly HK, Williams DJ, Zhu Y, Arnold SR, Ampofo K, Waterer GW, Levine M, Lindstrom S, Winchell JM, Katz JM, Erdman D, Schneider E, Hicks LA, McCullers JA, Pavia AT, Edwards KM, Finelli L., CDC EPIC Study Team. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med. 2015 Jul 30; 373(5): 415-27.
10. Hage CA, Knox KS, Wheat LJ. Endemic mycoses: overlooked causes of community acquired pneumonia. Respir Med. 2012 Jun; 106(6): 769-76.
11. Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, Edwards JR, Sievert DM. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data

Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. Infect Control Hosp Epidemiol. 2016 Nov; 37(11): 1288-1301.
12. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010 Aug 01; 51 Suppl 1: S81-7.
13. Prado, C.A.N. and Perloff, S., 2019. Pneumococcal infections (Streptococcus pneumoniae). Medsacpe.
14. Lei, B., Wang, S., Yu, L. and Ma, Q., 2025. Post-influenza bacterial infection: mechanisms of pathogenesis and advances in therapeutic strategies. Frontiers in Microbiology, 16, p.1673643.
15. Marrella, V., Nicchiotti, F. and Cassani, B., 2024. Microbiota and immunity during respiratory infections: lung and gut affair. International journal of molecular sciences, 25(7), p.4051.

How to cite this article:

Sadiq M. A. AL-Hiti, Ajwad Awad Assumaidaee and Maryam Maadh Badr. 2026. Lobar Pneumonia: Clinical Update, Advanced Management, and Emerging Science. *Int.J.Curr.Microbiol.App.Sci.* 15(9): 1-8.
doi: https://doi.org/10.20546/ijcmas.2026.1509.001